drugset / Trial / NCT00136435
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
Phase 2
Completed
100 enrolled
Dana-Farber Cancer Institute
Brigham and Women's Hospital · collabMassachusetts General Hospital · collabQueen Elizabeth II Health Sciences Centre · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and optimal dosing of L-asparaginase in adult patients with acute lymphoblastic leukemia (ALL) between the ages of 18 and 50 years.
Timeline
- Start
- 2002-06
- Primary completion
- 2008-11
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | asparaginase | Protein / enzyme biologic | — | Intramuscular |
| Background | 6-mercaptopurine (6-MP) | Unknown | — | Oral |
| Background | Cytarabine | Small molecule | — | Other |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Doxorubicin | Other / unclassified | — | Intravenous |
| Background | Hydrocortisone | Other / unclassified | — | Other |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Methotrexate | Small molecule | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | Vincristine | Small molecule | — | Intravenous |